Technical Analysis for HBP - Helix BioPharma Corp.

Grade Last Price % Change Price Change
grade F 0.88 -3.30% -0.030
HBP closed down 3.3 percent on Friday, June 5, 2020, on 1.31 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical HBP trend table...

Date Alert Name Type % Chg
Gilligan's Island Buy Setup Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -3.30%
NR7 Range Contraction -3.30%
Inside Day Range Contraction -3.30%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Helix BioPharma Corp. is an immuno-oncology company, which specializes in the field of cancer therapy. The Company is developing products for the prevention and treatment of cancer based on its technologies. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. The Company's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).
Medicine Medical Specialties Cancer Drugs Treatment Of Cancer Cancer Immunotherapy Tumor Monoclonal Antibodies Non Small Cell Lung Cancer Treatment Of Non Small Cell Lung Cancer

Is HBP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 2.01
52 Week Low 0.24
Average Volume 6,945
200-Day Moving Average 1.267
50-Day Moving Average 1.373
20-Day Moving Average 1.118
10-Day Moving Average 0.973
Average True Range 0.104
ADX 45.95
+DI 14.392
-DI 31.333
Chandelier Exit (Long, 3 ATRs ) 1.178
Chandelier Exit (Short, 3 ATRs ) 1.182
Upper Bollinger Band 1.436
Lower Bollinger Band 0.800
Percent B (%b) 0.13
BandWidth 56.941
MACD Line -0.145
MACD Signal Line -0.129
MACD Histogram -0.0167
Fundamentals Value
Market Cap 82.01 Million
Num Shares 93.2 Million
EPS -0.13
Price-to-Earnings (P/E) Ratio -6.77
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.895
Resistance 3 (R3) 0.893 0.887 0.893
Resistance 2 (R2) 0.887 0.883 0.888 0.892
Resistance 1 (R1) 0.883 0.880 0.885 0.885 0.891
Pivot Point 0.877 0.877 0.878 0.878 0.877
Support 1 (S1) 0.873 0.873 0.875 0.875 0.869
Support 2 (S2) 0.867 0.870 0.868 0.868
Support 3 (S3) 0.863 0.867 0.868
Support 4 (S4) 0.865